Cargando…

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

INTRODUCTION: Daratumumab, a human IgG monoclonal antibody targeting CD38, has demonstrated activity as monotherapy and in combination with standard-of-care regimens in multiple myeloma. Population pharmacokinetic analyses were conducted to determine the pharmacokinetics of intravenous daratumumab i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xu Steven, Dimopoulos, Meletios A., Sonneveld, Pieter, Ho, P. Joy, Belch, Andrew, Leiba, Merav, Capra, Marcelo, Gomez, David, Medvedova, Eva, Iida, Shinsuke, Min, Chang-Ki, Schecter, Jordan, Jansson, Richard, Zhang, Liping, Sun, Yu-Nien, Clemens, Pamela L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223994/ https://www.ncbi.nlm.nih.gov/pubmed/30374808 http://dx.doi.org/10.1007/s12325-018-0815-9

Ejemplares similares

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
por: Xu, XS, et al.
Publicado: (2017)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
por: Mateos, Maria-Victoria, et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
por: Bahlis, Nizar J., et al.
Publicado: (2020)

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
por: Suzuki, Kenshi, et al.
Publicado: (2018)

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
por: Xu, Xu Steven, et al.
Publicado: (2020)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
por: Avet-Loiseau, Hervé, et al.
Publicado: (2021)

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
por: Clemens, Pamela L., et al.
Publicado: (2016)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
por: Xu, Xu Steven, et al.
Publicado: (2017)

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
por: Theodorakakou, Foteini, et al.
Publicado: (2021)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
por: Durie, Brian G. M., et al.
Publicado: (2020)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2017)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
por: Mian, Hira, et al.
Publicado: (2022)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis
por: Menon, Trishala, et al.
Publicado: (2021)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
por: Weisel, Katja, et al.
Publicado: (2020)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
por: Htut, Thura W., et al.
Publicado: (2020)

Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?
por: Kalis, Joseph A.
Publicado: (2017)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
por: Agrawal, Soma, et al.
Publicado: (2020)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2a49lkbdu542383uuujb7s0m1t